Skip to main content

Advertisement

Table 1 Summary of neoepitope landscape in the PCGP cohort

From: The neoepitope landscape in pediatric cancers

Project Class Disease Patient number Sample numbera Average number of mutationsb Average number of neoepitope (≤500 nM)b Average number of expressed neoepitopesb
PCGP LEUKEMIA ETV 49 56 (7) 11.22 (20.73) 4.29 (9.25) 1.68 (4.09)
HYPER 53 53 9.49 4.11 -
BALL 31 31 11.58 5.03 2.00
HYPO 22 22 9.64 3.23 1.50
TALL 10 10 8.10 3.60 -
ERG 25 25 8.40 3.16 1.28
CBF 16 16 6.38 2.13 0.89
INF 19 21(2) 2.47 (3.57) 1.11 (1.52) 0.44 (0.44)
PHALL 35 35 4.49 1.83 0.52
E2A 21 21 5.48 2.10 -
AMLM7 3 3 2.67 0.67 0.33
Subtotal 284 293    
CNS HGG 32 35 (3) 17.97 (17.46) 8.59 (8.20) 3.68 (3.56)
EPD 32 34 (2) 5.06 (5.68) 1.78 (1.91) 0.93 (0.96)
MB 34 34 8.94 3.68 4.25
LGG 23 23 1.74 0.65 0.33
CPC 2 2 2.00 1.50 -
Subtotal 123 128    
SOLID MEL 4 4 112.25 51.25 6.00
NBL 44 47 (3) 15.2 (16.62) 7.09 (7.79) -
ACT 20 20 11.75 3.70 1.75
RHB 14 15 (1) 15.14 (18.00) 6.71 (8.13) 2.08 (3.14)
OS 27 27 18.22 7.07 2.92
RB 5 5 5.20 2.40 -
EWS 19 19 5.63 2.00 -
Subtotal 133 137    
TCGA   LUAD 129 129 226.63 95.74 36.99
LUSC 33 33 224.58 95.88 58.06
SKCM 133 133 411.50 167.57 60.64
Subtotal 295 295    
  1. aThe number in the parentheses denotes the number of relapse samples
  2. bThe number in the parentheses denotes the average number when relapse samples included